Scholar Rock Holding Corp (SRRK)
$57.80-$1.46 (-2.46%) Today
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 13 | 17,149 | $923K |
| Grant or award | 14 | 78,043 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
64 Form 4 filings on record, the earliest from Oct 7, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jeffrey S. Flier | Open-market sale | Common Stock | 1,568 | $53.53 | $84K | |
| Jeffrey S. Flier | Open-market sale | Common Stock | 1,470 | $54.24 | $80K | |
| Jeffrey S. Flier | Open-market sale | Common Stock | 15 | $54.88 | $823 | |
| Michael Gilman | Open-market sale | Common Stock | 1,346 | $53.54 | $72K | |
| Michael Gilman | Open-market sale | Common Stock | 1,155 | $54.23 | $63K | |
| Michael Gilman | Open-market sale | Common Stock | 43 | $54.81 | $2K | |
| Kristina Burow | Open-market sale | Common Stock | 2,105 | $53.49 | $113K | |
| Kristina Burow | Open-market sale | Common Stock | 948 | $54.28 | $51K | |
| Joshua Reed | Open-market sale | Common Stock | 2,105 | $53.50 | $113K | |
| Joshua Reed | Open-market sale | Common Stock | 948 | $54.28 | $51K | |
| Katie Peng | Open-market sale | Common Stock | 2,988 | $53.56 | $160K | |
| Katie Peng | Open-market sale | Common Stock | 2,437 | $54.25 | $132K | |
| Katie Peng | Open-market sale | Common Stock | 21 | $54.96 | $1K | |
| Jeffrey S. Flier - Director | Grant or award | Common Stock | 6,839 | $0.00 | - | |
| Jeffrey S. Flier - Director | Grant or award | Stock Option (Right to Buy) | 4,310 | $0.00 | - | |
| Joshua Reed - Director | Grant or award | Common Stock | 6,839 | $0.00 | - | |
| Joshua Reed - Director | Grant or award | Stock Option (Right to Buy) | 4,310 | $0.00 | - | |
| Richard Brudnick - Director | Grant or award | Common Stock | 6,839 | $0.00 | - | |
| Richard Brudnick - Director | Grant or award | Stock Option (Right to Buy) | 4,310 | $0.00 | - | |
| Kristina Burow - Director | Grant or award | Common Stock | 6,839 | $0.00 | - | |
| Kristina Burow - Director | Grant or award | Stock Option (Right to Buy) | 4,310 | $0.00 | - | |
| Michael Gilman - Director | Grant or award | Common Stock | 6,839 | $0.00 | - | |
| Michael Gilman - Director | Grant or award | Stock Option (Right to Buy) | 4,310 | $0.00 | - | |
| Katie Peng - Director | Grant or award | Common Stock | 6,839 | $0.00 | - | |
| Katie Peng - Director | Grant or award | Stock Option (Right to Buy) | 4,310 | $0.00 | - | |
 Srinivas Akkaraju - Director | Grant or award | Common Stock | 6,839 | $0.00 | - | |
| Srinivas Akkaraju - Director | Grant or award | Stock Option (Right to Buy) | 4,310 | $0.00 | - | |
| Kristina Burow - Director | Option exercise | Common Stock | 7,800 | $26.78 | $209K | |
| Kristina Burow - Director | Option exercise | Common Stock | 28,000 | $4.75 | $133K | |
| Kristina Burow - Director | Option exercise | Common Stock | 36,000 | $9.11 | $328K | |
| Kristina Burow - Director | Option exercise | Common Stock | 18,000 | $8.36 | $150K | |
| Kristina Burow - Director | Option exercise | Stock Option (Right to Buy) | 7,800 | $0.00 | - | |
| Kristina Burow - Director | Option exercise | Stock Option (Right to Buy) | 28,000 | $0.00 | - | |
| Kristina Burow - Director | Option exercise | Stock Option (Right to Buy) | 36,000 | $0.00 | - | |
| Kristina Burow - Director | Option exercise | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Keith Woods - Officer | Open-market sale | Common Stock | 10,220 | $49.57 | $507K | |
 Akshay Vaishnaw - Officer | Open-market sale | Common Stock | 12,246 | $49.57 | $607K | |
 Vikas Sinha - Officer | Open-market sale | Common Stock | 10,410 | $49.57 | $516K | |
 David Hallal - Officer | Open-market sale | Common Stock | 30,615 | $49.57 | $1.52M | |
| Mo Qatanani - Officer | Open-market sale | Common Stock | 7,427 | $46.94 | $349K | |
| Mo Qatanani - Officer | Open-market sale | Common Stock | 857 | $47.86 | $41K | |
| Mo Qatanani - Officer | Open-market sale | Common Stock | 200 | $48.48 | $10K | |
| Jing L. Marantz - Officer | Open-market sale | Common Stock | 4,157 | $46.53 | $193K | |
| Junlin Ho - Officer | Open-market sale | Common Stock | 9,580 | $46.53 | $446K | |
| Caryn Parlavecchio - Officer | Open-market sale | Common Stock | 9,035 | $46.53 | $420K | |
| Mo Qatanani - Officer | Open-market sale | Common Stock | 7,989 | $46.53 | $372K | |
| Akshay Vaishnaw - Officer | Grant or award | Common Stock | 47,021 | $0.00 | - | |
| Vikas Sinha - Officer | Grant or award | Common Stock | 47,021 | $0.00 | - | |
| Mo Qatanani - Officer | Grant or award | Common Stock | 29,258 | $0.00 | - | |
| Caryn Parlavecchio - Officer | Grant or award | Common Stock | 29,258 | $0.00 | - | |
| Jing L. Marantz - Officer | Grant or award | Common Stock | 34,482 | $0.00 | - | |
| Junlin Ho - Officer | Grant or award | Common Stock | 36,572 | $0.00 | - | |
| David Hallal - Officer | Grant or award | Common Stock | 128,004 | $0.00 | - | |
| Keith Woods - Officer | Grant or award | Common Stock | 47,021 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Scholar Rock Holding Corp (SRRK) had 12 insider filings in the last 90 days, with the most recent on 2026-07-06. The full record for SRRK runs to 64 Form 4 filings, the earliest from 2024-10-07. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of SRRK were filed in the last 90 days. 9 purchases are on record for this company.
13 insider sales of SRRK were filed in the last 90 days, totaling $923K.
This page tracks SRRK Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add SRRK to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
